BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
What is the purpose of this trial?
The study is designed to develop individualized targeted therapy based on the identification and validation of specific molecular pathways of non-small cell lung cancer (NSCLC.) To address these new targeted therapeutic approaches, we propose to implement a translational lung cancer research program entitled, “BATTLE-2: Biomarker-integrated Approaches of Targeted Therapy of Lung Cancer Elimination-2,” and provide a strong rationale-based targeted treatment strategy. The program required that all eligible subjects with advanced NSCLC undergo a core biopsy of their tumors and applied biomarkers in the selection of individualized targeted therapy.
- 18 and older
- MD Anderson Cancer Center
- Last Updated:
- Study HIC#:
Clinicaltrials.gov ID: Yale0186992